Patent EA-004859-B1 (EA)
Title: New cycloheptene compounds and pharmaceutical compositions containing them
Inventor: CASARA PATRICK
IPC: C07D233/54
Filed: 2002-01-17
Abstract: 1. Compounds of formula (I): wherein : X represents a bond or a group selected from alkylene, CO, S(O)m (-S(O)n-, A1-, (-CO-A1-, -A1-S(O)n-A'1- and -A1-CO-A'1- (wherein A1 and A'1, identical or different, represent an alkylene group and n is 0, 1 or 2), the symbol "(" indicating the point of attachment of those groups to the cycloheptene, Y represents an aryl, heteroaryl, cycloalkyl or heterocycloalkyl group, each of those groups being unsubstituted or substituted by one or more, identical or different, R8 groups, R1, R2, R3 and R4 each independently of the others represent a hydrogen atom or an aryl, heteroaryl, cycloalkyl or heterocycloalkyl group, each of those groups being unsubstituted or substituted by one or more, identical or different, R8 groups, or R1, R2, R3 and R4, taken in pairs, together form a bond, or R1 and R2, or R2 and R3, or R3 and R4, taken in pairs with the carbon atoms to which they are bonded, form a fused benzene ring or a fused aromatic or partially unsaturated heterocycle, having 5 or 6 ring members and containing 1 or 2 hetero atoms selected from nitrogen, oxygen and sulphur, on the understanding that only one ring can be fused on the 7-membered structure, T represents a -CH(R5)-, -N(R5)- or (-N(R5)CO-group (wherein R5 represents a hydrogen atom or an alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl group, each of those groups being unsubstituted or substituted by one or more, identical or different, R7 groups), the symbol "*" indicating the point of attachment of the group to the cycloheptene, V represents a hydrogen atom or an aryl or heteroaryl group, each of those groups being unsubstituted or substituted by one or more, identical or different, R7 groups, A2 represents a [C(R6)(R'6)]p-group wherein p is 0, 1,2, 3 or 4 when T represents a -CH(R5)- or *-N(R5)CO-group, or p is 1, 2, 3 or 4 when T represents an -N(R5)-group; and R6 and R'6, which may be identical or different, represent a hydrogen atom or an alkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl or optionally substituted heterocycloalkylalkyl group, an R9 group or an alkyl group substituted by an R9 group (wherein R9 represents an -OR5-, -N(R5)(R'5), -S(O)mR5, -CON(R5)(R'5), -N(R5)COR'5, -N(R5)SO2R'5, -SO2N(R5)(R'5) or -N(R5)COO(R'5)-group, m being 0,1 or 2, and R'5 can have any of the meanings of R5), R7 represents a halogen atom or an alkyl, alkoxy, hydroxy, mercapto, alkylthio, cyano, amino (optionally substituted by one or two alkyl groups), nitro, carboxy, alkoxycarbonyl, aminocarbonyl (optionally substituted by one or two alkyl groups), carbamoyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocycloalkyl or unsubstituted or substituted heterocycloalkylalkyl group, R8 represents a halogen atom, or an oxo, hydroxy, cyano, nitro, carboxy, alkoxycarbonyl or perhaloalkyl group or a -U-R80 or -A80-U-R80 group (wherein A80 represents an alkylene group; U represents a bond, an oxygen atom or a group selected from NH, S(O)m, NHCO, CONH, SO2NH and NHSO2, m being 0, 1 or 2; and R80 is a group selected from alkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl), it being understood that: - the term "alkyl" denotes a linear or branched group containing from 1 to 6 carbon atoms, - the term "alkylene" denotes a linear or branched bivalent group containing from 1 to 6 carbon atoms, - the term "cycloalkyl" denotes a saturated cyclic group containing from 3 to 8 carbon atoms, - the term "heterocycloalkyl" denotes a saturated or partially unsaturated cyclic group having from 5 to 7 ring members and containing from 1 to 3 hetero atoms selected from nitrogen, oxygen and sulphur, - the term "aryl" denotes a phenyl or naphthyl group, - the term "heteroaryl" denotes a mono- or bi-cyclic group that is aromatic or contains at least one aromatic ring, has from 5 to 11 ring members and contains from 1 to 5 hetero atoms selected from nitrogen, oxygen and sulphur, - the term "substituted" applied to the terms "aryl", "heteroaryl", "cycloalkyl" and "heterocycloalkyl" means that those groups may be substituted by one or more identical or different groups selected from cyano, alkylcarbonyl, aminocarbonyl (optionally substituted by one or two alkyl groups) and halogen atoms, - the term "substituted" applied to the terms "arylalkyl", "heteroarylalkyl", "cycloalkylalkyl" and "heterocycloalkylalkyl" means that the cyclic moiety of those groups may be substituted by one or more identical or different groups selected from oxo, cyano, alkylcarbonyl, aminocarbonyl (optionally substituted by one or two alkyl groups) and halogen atoms, their enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base. 2. Compounds of formula (I) according to claim 1, wherein X represents a bond, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 3. Compounds of formula (I) according to claim 1, wherein Y represents an aryl group optionally substituted by R8, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 4. Compounds of formula (I) according to claim 1, wherein each of R1, R2, R3 and R4 represents a hydrogen atom, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 5. Compounds of formula (I) according to claim 1, wherein T represents an -N(R5)- group, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 6. Compounds of formula (I) according to claim 5, wherein T represents an -NH- group, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 7. Compounds of formula (I) according to claim 1, wherein A2 represents a -CH2- or -CH2-CH2- group, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 8. Compounds of formula (I) according to claim 1, wherein A2 represents a (4-cyano-phenyl)methylene, (4-chlorophenyl)methylene, (4-cyanobenzyl)methylene or (4-chloro-benzyl)methylene group, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 9. Compounds of formula (I) according to claim 1, wherein V represents a heteroaryl group optionally substituted by R7, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 10. Compounds of formula (I) according to claim 1, wherein V represents an imidazolyl group optionally substituted by R7, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 11. Compounds of formula (I) according to any one of claims 9 and 10, wherein R7 represents an unsubstituted or substituted arylalkyl group or an unsubstituted or substituted heteroaryl group, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 12. Compounds of formula (I) according to claim 1, wherein X represents a bond; Y represents an aryl group optionally substituted by R8; each of R1, R2, R3 and R4 represents a hydrogen atom; T represents an -NH- group; A2 represents a -CH2, -CH2-CH2-, (4-cyanophenyl)methylene, (4-chlorophenyl)methylene, (4-cyanobenzyl)methylene or (4-chlorobenzyl)methylene group; and V represents a heteroaryl group optionally substituted by R7, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 13. Compounds of formula (I) according to claim 1, wherein X represents a bond; Y represents an aryl group optionally substituted by R8; each of R1, R2, R3 and R4 represents a hydrogen atom; T represents an -NH- group; A2 represents a -CH2, -CH2-CH2-, (4-cyanophenyl)methylene, (4-chlorophenyl)methylene, (4-cyanobenzyl)methylene or (4-chlorobenzyl)methylene group; and V represents an imidazolyl group optionally substituted by R7, their enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 14. Compounds of formula (I) according to claim 1 which are (R,S)-4-{[5-({[3-(2-methylphenyl)-2-cyclohepten-1-yl]amino}methyl)-1H-imidazol-1-yl]methyl}benzonitrile, 4-{[5-({[3-(3-methylphenyl)-2-cyclohepten-1-yl]amino}methyl)-1H-imidazol-1-yl]-methyl}benzonitrile and 4-{[5-({[3-(3-chlorophenyl)-2-cyclohepten-1-yl]amino}methyl)-1H-imidazol-1-yl]methyl}benzonitrile. 15. Pharmaceutical compositions for use as a medicament in the treatment of cancerous diseases comprising as active ingredient at least one compound according to any one of claims 1 to 14, alone or in combination with one or more inert, non-toxic, pharmaceutically acceptable excipients or carriers. 16. Pharmaceutical compositions for use as a medicament in the treatment of restenosis after angioplasty or vascular surgery and in the treatment of type I neurofibromatosis comprising at least one active ingredient according to any one of claims 1 to 14 alone or in combination with one or more inert, non-toxic, pharmaceutically acceptable excipients or carriers.